rediem | $1,200,000 | (Dec 4, 2024)
Fello(US) | $10,400,000 | (Dec 4, 2024)
Refoxy Pharma | $9,561,279 | (Dec 4, 2024)
MimiVax, LLC
United States
- Buffalo, NY
- 10/12/2021
- Unknown
- $5,000,000
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.
SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)
- Industry Pharmaceutical Manufacturing
- Website https://www.mimivax.com/
- LinkedIn https://www.linkedin.com/company/mimivax-llc/
Related People
Michael CiesielskiFounder
United States -
Buffalo-Niagara Falls Area
At MimiVax, our mission is to disrupt cancer. To increase survival and send hope through the development of highly innovative immunotherapies aimed at improving patient's lives.
Stackfix | $3,000,000 | (Dec 4, 2024)
Droxi | $21,000,000 | (Dec 4, 2024)
Maze Therapeutics | $115,000,000 | (Dec 4, 2024)
Nurture Boss | $4,025,000 | (Dec 4, 2024)
ENAKL | $1,400,000 | (Dec 4, 2024)
MakersHub | $7,000,000 | (Dec 4, 2024)
Freckle (freckle.io) | $1,900,000 | (Dec 3, 2024)
AdvantageClub.ai | $4,000,000 | (Dec 3, 2024)